Shephard Mpofu

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations

Life Sciences, Immunology, Pharmacotherapy +15

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Philip J. Mease, Iain B. McInnes, Bruce Kirkham et al. · New England Journal of Medicine · 2015 · 740 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 301 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · Annals of the Rheumatic Diseases · 2012 · 288 citations

Life Sciences, Immunology, Pharmacotherapy +17